HOME >> MEDICINE >> NEWS
European commission grants "orphan" status for new acute myeloid leukaemia treatment

Wyeth-Ayerst Pharmaceuticals, the pharmaceutical division of American Home Products Corporation (NYSE:AHP),announced today that the European Commission has designated Mylotarg(gemtuzumab ozogamicin)as an "orphan medicinal product." The Commission decision follows a positive opinion adopted on 13 September 2000 by the Committee on Orphan Medicinal Products (COMP) of the European Agency for the Evaluation of Medicinal Products (EMEA).

"We anticipate that Mylotarg will become an important treatment option for European patients aged 60 and over with CD33-positive relapsed acute myeloid leukaemia (AML)," says L. Patrick Gage, Ph.D., President, Wyeth-Ayerst Research. "Its mechanism of action focuses on using antibody-antigen specificity to target delivery of potent chemotherapy to myeloid leukaemic cells. This compound represents the first product from Wyeth's promising oncology pipeline."

As a designated orphan medicinal product, Mylotarg will have access to the Commission's "centralised" procedure for assessment of the marketing authorisation application. Orphan medicinal products are intended to treat patients with rare life-threatening or very serious diseases for which no satisfactory method of treatment exists or where the product will be of significant benefit.

Orphan medicinal products do not automatically qualify for approval under "exceptional circumstances," but companies that sponsor orphan products receive incentives for bringing these products to the market and to the patient. Such incentives include the possibility of protocol assistance from the EMEA and fee reductions for all types of centralised marketing authorisation evaluation activities. If approved by the EMEA, Mylotarg would be the first product available in Europe from a new class of anticancer therapy known as "antibody-targeted chemotherapy." Mylotarg utilizes a patented linker technology with a novel potent anti-tumor antibiotic, calicheamicin.

Mylotarg is being develo
'"/>

Contact: Roseann Ward
roseann.ward@ketchumcomms.co.uk
44-0-207-465-8752
Ketchum
14-Nov-2000


Page: 1 2 3

Related medicine news :

1. ESC releases the first European Guidelines on Percutaneous Coronary Interventions (PCI)
2. The European Society of Cardiology launches Women at Heart
3. Use of potentially inappropriate medications among elderly common in some European countries
4. European folic acid policies are not effective enough
5. New European cancer figures for 2004 major efforts needed against the big four killers
6. Third of European cancer patients use complementary and alternative therapies
7. A new service from the European Patent Office
8. European study highlights persistent 3 decade increase in childhood cancer incidence
9. European nations urged to ratify international treaty on tobacco control
10. Increased investment in radiotherapy will improve cure rates for European cancer patients
11. ESA looking for more European women to volunteer for WISE bed-rest study in Toulouse next year

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/26/2017)... ... 2017 , ... After a summer-long contest to crown the ... Drivers proudly announced the winners of the HEROtini Mocktail Challenge at the Stockton ... the challenge of competing in three categories: Best HEROtini Mocktail, Top HEROtini Bartender, ...
(Date:9/26/2017)... ... , ... Data Integrity: , The Key to FDA and GMP Compliance, ** ... http://www.fdanews.com/fdadataintegrity , Consider this situation. The FDA gives simple ... be trustworthy and reliable … a more detailed evaluation may be warranted.” , ...
(Date:9/26/2017)... ... 26, 2017 , ... Dr. Kovatis, is a Hospital for ... and Foot Section of the Department of Orthopedic Surgery at Hackensack University Medical ... UMC performing total ankle replacements. Because of this, Dr. Kovatis is often referred ...
(Date:9/26/2017)... , ... September 26, 2017 , ... The 2017 American ... called “The Magic of Fat,” revealed not only the latest about cosmetic procedures to ... be an evolution in cosmetic medicine. , “Fat really is magical, especially when it ...
(Date:9/26/2017)... ... 26, 2017 , ... The Organizing Committee is pleased to ... Pittcon 2018. As of July 1, Adrian C. Michael, Ph.D. (University of Pittsburgh, ... Charles Gardner, (ChemImage Corporation) and selected chairs. , Other members of ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... 2017 EpiVax, Inc. ("EpiVax") a ... immune engineering, today announced a new NIH-funded ... ... and presents a challenge for traditional flu ... be effective. Using state-of-the-art bioinformatics and molecular modeling methods, ...
(Date:9/12/2017)... 2017  ValGenesis Inc., the global leader in ... to announce the appointment of Dr. Ajaz ... of Directors and Chairman of Advisory Board beginning ... companies to manage their entire validation lifecycle process ... this process. Furthermore, ValGenesis VLMS enables rigorous compliance, ...
(Date:9/7/2017)...  Eli Lilly and Company (NYSE: ... to more efficiently focus resources on developing new ... workforce reductions, including those from a U.S. voluntary ... 3,500 positions. With the streamlining ... approximately $500 million that will begin to be ...
Breaking Medicine Technology:
Cached News: